Trial
NCT05126303
Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Guard Therapeutics AB
Collaborators
—
Condition
Acute Kidney Injury
Intervention
RMC-035
Why stopped
Enrollment discontinued following DMC recommendation based on futility with regards to primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-16